Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations

International Journal of Cancer

Volumn 99, Issue 1, 2002, Pages 82-87

  Geertsen, Ralf ^a,b   Böni, Roland ^a   Blasczyk, Rainer ^c   Romero, Pedro ^d   Betts, David ^e   Rimoldi, Donata ^f   Hong, Xin ^a   Laine, Elisabeth ^a   Willers, Jörg ^a   Dummer, Reinhard ^a,g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Medica ^*  (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Genomic abbreviations; HLA; Melanoma

Indexed keywords

HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CHROMOSOME 6P; CONTROLLED STUDY; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

ALLELES; ANTIGENS, NEOPLASM; CHROMOSOMES, HUMAN, PAIR 6; FLOW CYTOMETRY; GENES, MHC CLASS I; HLA-A2 ANTIGEN; HUMANS; KARYOTYPING; LOSS OF HETEROZYGOSITY; MELANOMA; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0036568424     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10284     Document Type: Article

References (44)

1. Peptide antigen production by the proteasome: Complexity provides efficiency
2. Tumor antigens recognized by T cells
3. Frequent cytolytic T-cell responses to peptide MAGE-A 10(254-262) in melanoma
4. 4+ T-cells
5. Loss of HLA Class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
6. Loss of HLA haplotype and B locus downregulation in melanoma cell lines
7. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma
8. Lack of HLA Class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA
9. Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression
10. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression
11. Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines
12. Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-gamma
13. Quantitative correlation between HLA Class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes
14. HLA Class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines
15. Chromosome loss with concomitant duplication and recombination both contribute most to loss of heterozygosity in vitro
16. MHC antigens in human melanomas
17. Selective loss of human leukocyte antigen Class I allele expression in advanced renal cell carcinoma
18. HLA-DR typing by PCR amplification with sequence specific primers in two hours
19. Chromosomal allele loss in primary cutaneous melanoma is heterogeneous and correlates with proliferation
20. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors
21. Sequence analysis of the 2nd intron revealed common sequence motifs providing the means for a unique sequencing based typing protocol of the HLA-A locus
22. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29122 and SK-MEL-29129
23. Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions
24. C-myc represses transiently transfected HLA Class I promoter sequences not locus-specifically
25. Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma
26. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
27. Recognition of HLA-A1 by murine monoclonal antibodies
28. The EORTC Melanoma Group exchange program: Evaluation of a multicenter monoclonal antibody study
29. Inverse regulation of neuronal cellular adhesion molecule (NCAM) by IFN-g in melanoma cell cultures from CNS lesions
30. Routine karyotyping in Wilms tumor
31. The sebaceous nevus: A nevus with deletion of the PTCH gene
32. Tissue typing the HLA-A locus from genomic DNA by sequence- specific PCR: Comparison of HLA genotype and surface expression on colorectal tumor cell lines
33. A comprehensive PCR-SSP typing system for identification of HLA-A locus alleles
34. Sequencing of HLA Class I genes based on the conserved diversity of the noncoding regions: Sequencing-based typing of the HLA-A gene
35. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue
36. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immuno-dominant peptide of the human melanoma antigen MART-1
37. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
38. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1A1
39. Immune escape mechanisms in malignant melanoma
40. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines
41. Molecular classification of cutaneous malignant melanoma by gene expression profiling
42. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo
43. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
44. 8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients